Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK101 Bioequivalence Study in Healthy Volunteers
NCT03876210Phase 1Completed
- Sponsor
- PMG Pharma
- Start
- Jul 2019
- Primary completion
- Jul 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of celecoxib and PG201 in osteoarthritis (OA) (2 arms), sponsored by PMG Pharma. Primary endpoints: Area Under the Concentration-time Curve from Time Zero to the Last Quantifiable Concentration and Maximum Plasma Concentration. Started Jul 2019; status: completed.
02
Drugs
celecoxibPG201
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03876210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03876210.